NFKB1 and Miyoshi myopathy: Considering the core downstream pathways that RTKs signaling cascades converge at, we investigated the effects of anlotinib on those pathways and found that anlotinib inhibits the MAPK, PI3K/Akt/mTOR, JAK/STAT, and NF-κB pathways in MM cells.